Litcius/Paper detail

Add-on value of tirzepatide versus semaglutide

André Scheen

2022The Lancet Diabetes & Endocrinology12 citationsDOI

Topics & Concepts

MedicineType 2 diabetesInsulin resistanceIncretinSemaglutideDiabetes mellitusGlucagon-like peptide 1 receptorDulaglutideInternal medicineEndocrinologyInsulinAdverse effectPharmacologyAgonistLiraglutideReceptorBioinformaticsBiologyDiabetes Treatment and ManagementPharmacology and Obesity TreatmentMetabolism, Diabetes, and Cancer
Add-on value of tirzepatide versus semaglutide | Litcius